Dermatology

Posters presented at the Society for Pediatric Dermatology Annual Meeting shed new light on pediatric hair loss, including the rising prevalence of androgenetic alopecia in children, the potential of artificial intelligence to assess hair loss severity, and the long-term safety of ritlecitinib for treating alopecia areata in adolescents.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, discusses various effective treatments for alleviating itch in patients with atopic dermatitis (AD), including dupilumab and Janus kinase (JAK) inhibitors.

A dermatologist provides clinical insights on managing pain in patients with hidradenitis suppurativa.

An expert on hidradenitis suppurativa gives an overview of the current research landscape, highlighting exciting developments in the treatment space.

Two posters presented at the Society for Pediatric Dermatology Annual Meeting explored common health conditions linked to childhood alopecia areata and the effectiveness of dupilumab treatment in children with both alopecia areata and atopic dermatitis.

Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.

A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.

Patients with atopic dermatitis who use oral corticosteroids for more than 90 days have a slightly increased risk of adverse events like myocardial infarction and hyperlipidemia.

The Society for Pediatric Dermatology (SPD) Annual Meeting focused on different aspects of pediatric dermatology, including topical treatments, technology, and misinformation.

A literature review found a link between COVID-19 vaccination and alopecia, with most cases experiencing hair loss within 1 month after the first dose. However, the small sample size and limited data call for further investigation.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

Vivian Shi, MD, FAAD, provides an overview of current treatment guidelines for hidradenitis suppurativa and discusses ways to improve upon them.

An expert on hidradenitis suppurativa (HS) provides an overview of the Hurley staging system and discusses unmet needs in the overall treatment landscape.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Posters presented at the Society for Pediatric Dermatology Annual Meeting found that pediatric deroofing can lead to patient satisfaction later in life.

Updates in nonsteroidal topical therapies were presented during a session at the Society for Pediatric Dermatology Annual Meeting.

A presentation at the Society for Pediatric Dermatology Annual Conference discussed how to use generative artificial intelligence (AI) to improve processes while working in the dermatology space.

The Society for Pediatric Dermatology (SPD) Annual Meeting featured a new debates segment where experts in the field discussed preferred strategies for the treatment of pediatric skin conditions.

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo.

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older.

Patients with vitiligo have a higher genetic risk of developing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Iltefat Hamzavi, MD, discusses the importance of support groups and other helpful resources for families and caregivers of patients with hidradenitis suppurativa and provides closing thoughts for clinical providers.

Dr Hamzavi discusses how clinicians can address the psychosocial impact of hidradenitis suppurativa on patients and the rate of hospitalization.

The annual meeting will take place in Toronto July 11-15, 2024.

Iltefat Hamzavi, MD, outlines comorbidities associated with hidradenitis suppurativa and discusses best practices for coordinating care between specialists.